



The patients perspective on the needs for reduced inequalities and greater patient engagement

Stefania Vallone

stefania.vallone@womenagainstlungcancer.eu

www.womenagainstlungcancer.org

15th December 2021

- Every year millions of people are diagnosed with cancer
- Scientific advances have improved the options to fight against cancer
- **The advent of *precision medicine* marked a new era in the treatment of advanced NSCLC**

Recent studies have identified a *growing number of rare molecular alterations*

The *tumor molecular profiling* has become a key aspect of the therapeutic decision-making process

Molecular diagnostics and innovative treatments offer *important benefits* to patients



BUT

- ✓ They need to be available and reimbursed
- ✓ There is a strong evidence that access still remains inequitable across Europe

People with cancer CAN NOT WAIT!

They deserve to have the SAME OPPORTUNITIES to be cured

NOW, it's time to ensure the implementation and turn the plan into reality



Barriers for the adoption of Comprehensive Biomarker Testing



Costs & Reimbursement



**Disparities in
healthcare resources**

**Awareness & Education
Gaps**



**HCP awareness and
understanding of testing
options available**



**Patient awareness and
empowerment to request
for testing (individual level)**



2019 Availability of Biomarker Testing in Europe

	ALK	EGFR	PD-L1	ROS1	BRAF	MET	KRAS
Croatia	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Not reimbursed	Not reimbursed
Denmark	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Contradictory data	Reimbursed	Reimbursed
Finland	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Not reimbursed	No data
France	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed
Germany	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed
Ireland	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed
Israel	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Reimbursed
Italy	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed
Latvia	Not reimbursed	Reimbursed	Not reimbursed	Not reimbursed	Not reimbursed	Not reimbursed	No data
Norway	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	No data
Poland	Reimbursed	Reimbursed	Contradictory data	Reimbursed	Not reimbursed	Not reimbursed	Not reimbursed
Portugal	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Contradictory data	No data
Romania	Contradictory data	Contradictory data	Contradictory data	Not reimbursed	Not reimbursed	Not reimbursed	Not reimbursed
Slovenia	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed
Spain	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Not reimbursed	Not reimbursed
Sweden	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed
Switzerland	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	No data
The Netherlands	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed
Turkey	Reimbursed	No data	Not reimbursed	No data	Not reimbursed	No data	Reimbursed
United Kingdom	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Contradictory data	Reimbursed	Not reimbursed


Table 1. Availability of lung cancer molecular tests (November 2019).

Reimbursed

Not reimbursed

Contradictory data

With reimbursement, we refer to tests that are available for all patients, and therefore are not self-paid by the patient




What is the situation

Reimbursed Not reimbursed Contradictory data With reimbursement, we refer to drug


Table 2. Availability of lung cancer drugs (November 2019).

	CROATIA	DENMARK	FINLAND	FRANCE	GERMANY	IRELAND	ISRAEL	ITALY	LATVIA
Afatinib (indic. 1)	Reimbursed	Contradictory data	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed
Afatinib (indic. 2)	Not reimbursed	Contradictory data	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Reimbursed	Not reimbursed	Reimbursed
Abraxane	Not reimbursed	Reimbursed	Reimbursed	Not reimbursed	Reimbursed	Not reimbursed	Not reimbursed	Not reimbursed	Not reimbursed
Pembrolizumab (indic. 1)	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed
Pembrolizumab (indic. 2)	1	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Reimbursed	Reimbursed	Not reimbursed
Pembrolizumab (indic. 3)	Not reimbursed	Not reimbursed	Reimbursed	Not reimbursed	Reimbursed	Not reimbursed	Reimbursed	Reimbursed	Not reimbursed
Pembrolizumab (indic. 4)	Not reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Reimbursed	Reimbursed	Not reimbursed
Osimertinib	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Reimbursed	4	Not reimbursed
Gefitinib	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed
Durvalumab	Not reimbursed	2	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Reimbursed	Reimbursed	Not reimbursed
Crizotinib (indic. 1)	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	5
Crizotinib (indic. 2)	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	5
Crizotinib (indic. 3)	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	5
Brigatinib	Reimbursed	Reimbursed	Reimbursed	3	Reimbursed	Reimbursed	Reimbursed	Not reimbursed	Not reimbursed
Nivolumab	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed
Ceritinib	Not reimbursed	Reimbursed	Not reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed
Alectinib (indic. 1)	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed
Alectinib (indic. 2)	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed
Atezolizumab	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Reimbursed	Not reimbursed




68% of drugs indications analyzed in this paper are not reimbursed in Latvia. Half of indications are not reimbursed in Romania and Poland.

What is the situation about access to **Clinical Trials**?



According to ClinicalTrials.gov, there are more than **421 clinical trials recruiting patients in Europe** (accessed 31 October 2019).

France, Italy, Spain, Germany and UK conduct the majority of trials



Some proposals to improve access and reduce disparities

- 1. Awareness campaigns** to increase education and understanding of the benefits of biomarker testing
- 2. Increasing funds** to build the infrastructures required to perform comprehensive biomarker testing
- 3. Implementation of MTBs** to provide accurate diagnosis and formulate a plan for every patient
- 4. Development and accreditation** of centers of excellence in specific disease
- 5. Development of expanded access/compassionate access programs** to promote access to drugs, which have been approved by the EMA, but are not yet reimbursed.
- 6. Development and harmonization of guidelines** across Europe





European Program for **R**outine testing of **P**atients with **A**dvanced lung cancer



To increase their molecular screening



To facilitate their accrual in clinical trials



To provide them a logistic support

www.epropa.eu

FOR WITHOUT
INNOVATION, THERE
IS NO FUTURE

Innovation is not truly innovation, if people do not have access

